FDA approves three treatments for diabetes

Share this article:
FDA approves three treatments for diabetes
FDA approves three treatments for diabetes

Takeda announced that the FDA has approved Nesina (alogliptin), Oseni (alogliptin and Pioglitazone), and Kazano (alogliptin and metformin HCl) for the treatment of type 2 diabetes in adults as adjuncts to diet and exercise. Federal approval was based on worldwide placebo- and active-controlled clinical trials of Nesina involving more than 13,000 patients.

Nesina is a dipeptidyl peptidase-4 inhibitor (DPP-4i) that slows the inactivation of incretin hormones GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic peptide). Oseni, which combines alogliptin with pioglitazone, is the first to include both a DPP-4i and a thiazolidinedione (TZD) in a single tablet. Kazano combines alogliptin with metformin HCl, a biguanide also indicated for the treatment of diabetes.

Share this article:

More in Products

Bertlesmann buys Relias Learning

Bertelsmann, a media company based in Germany, said last week it is buying Relias Learning from its current owners, Vista Equity Partners and LLR Partners.

Acuity Brands introduces LED collection

Acuity Brands introduces LED collection

Acuity Brands says its new CanoeTM LED Pendant and Sconce Collection from Winona Lighting® can meet the needs of designers in unique spaces.

SwimEx debuts Triton Pool

SwimEx debuts Triton Pool

SwimEx Inc. has announced the Triton, the newest member of its line of fitness and therapy pools. It is available for the commercial and residential markets.